Vision Loss News and Research

RSS

hESC-derived cells offer source of macular tissue repair and replacement

Subretinal transplantation of retinal pigment epithelium derived from human embryonic stem cells appears to be a well-tolerated means of treating age-related macular degeneration and Stargardt’s macular dystrophy, suggest two open-label phase I/II studies.

19 May 2015

Envision presents awards for work in low vision rehabilitation

Envision presents the Lifetime Achievement Award from time-to-time to researchers whose careers have been marked by outstanding, creative and important contributions to low vision research...

14 May 2015

UC Irvine study opens door to novel treatments for people with retinal damage

Driving down a dimly lit road at midnight can tax even those with 20/20 vision, but according to a recent UC Irvine study, the brain processes the experience no differently than if it were noon. The same study also reveals how quickly the brain adapts to vision loss, contradicting earlier research and opening the door to novel treatments.

12 May 2015

Gene therapy is key to addressing Sanfilippo Syndrome, say Ohio scientists and clinicians

Gene therapy is the delivery of DNA into a patient's cells to replace faulty or missing genes—or adds new genes—in an attempt to cure cancer or make changes so the body is better able to fight off disease. Scientists and clinicians have identified a number of different ways to do this, in an effort to correct malfunctioning or mutated genes. Many gene therapy clinical trials are ongoing to assess the safety and potential benefits in patients with rare diseases.

8 May 2015

AIDS patients at increased risk of developing intermediate-stage AMD

Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) presented today at the 2015 ARVO Annual Meeting in Denver, CO.

5 May 2015

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.

4 May 2015

OAO report calls for better care for people living with eye disease, vision problems in Ontario

By 2031, the number of Ontarians living with eye disease and vision problems, already in the millions, is expected to double. This leads to significant costs for Ontario's healthcare system, with vision loss already costing the province $7.3 billion annually.

28 Apr 2015

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease.

28 Apr 2015

Dr. Mike O. Karl awarded EYEnovative Research Award for retina research

Dr. Mike O. Karl, group leader at the German Center for Neurodegenerative Diseases and the DFG Research Center for Regenerative Therapies Dresden - Cluster of Excellence at the TU Dresden, was awarded the “EYEnovative Förderpreis” of the Novartis Pharma GmbH already for the second time.

25 Apr 2015

New research examines what happens when MS patients discontinue their medication

New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication.

22 Apr 2015

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

There are two forms of macular degeneration: the wet form and the dry form. The dry form is less challenging as it affects a smaller number of people and the disease progression is far slower...

21 Apr 2015

Research: Stem cell injection may soon slow or reverse effects of age-related macular degeneration

An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai. Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.

16 Apr 2015

Eyenuk's EyeArt automated high-throughput diabetic retinopathy screening receives CE Mark

Eyenuk, Inc. announced today that it received CE Marking for its pioneering EyeArt software, a suite of advanced image analysis tools for automated high-throughput screening of diabetic retinopathy. The company plans to launch its product in select leading eye care sites across Europe in the next few months.

14 Apr 2015

UC Davis' John S. Werner wins 2015 Verriest Medal from International Colour Vision Society

John S. Werner, a UC Davis neuroscientist and international authority on visual perception, has been selected to receive the 2015 Verriest Medal from the International Colour Vision Society for his contributions to understanding the structural and functional basis of color vision, how and why vision changes across the life span, and factors that contribute to loss of vision associated with disease. He will receive the award at the society's biennial symposium in Sendai, Japan, in July.

2 Apr 2015

Wearable collision warning device may help patients with peripheral vision loss

People who have lost some of their peripheral vision, such as those with retinitis pigmentosa, glaucoma, or brain injury that causes half visual field loss, often face mobility challenges and increased likelihood of falls and collisions.

30 Mar 2015

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung.

6 Mar 2015

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe.

23 Feb 2015

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss.

23 Feb 2015

IUPUI's Jason Meyer awarded $1.8 million NIH grant to explore how glaucoma develops in stem cells

Jason Meyer, Ph.D., assistant professor of biology in the School of Science at Indiana University-Purdue University Indianapolis, has received a National Institutes of Health grant to study how glaucoma develops in stem cells created from skin cells genetically predisposed to the disease.

20 Feb 2015

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.

20 Feb 2015

Vision Loss News and Research

hESC-derived cells offer source of macular tissue repair and replacement

Envision presents awards for work in low vision rehabilitation

UC Irvine study opens door to novel treatments for people with retinal damage

Gene therapy is key to addressing Sanfilippo Syndrome, say Ohio scientists and clinicians

AIDS patients at increased risk of developing intermediate-stage AMD

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

OAO report calls for better care for people living with eye disease, vision problems in Ontario

TSRI study provides new insight into preventing diseases that cause vision loss in adults

Dr. Mike O. Karl awarded EYEnovative Research Award for retina research

New research examines what happens when MS patients discontinue their medication

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Research: Stem cell injection may soon slow or reverse effects of age-related macular degeneration

Eyenuk's EyeArt automated high-throughput diabetic retinopathy screening receives CE Mark

UC Davis' John S. Werner wins 2015 Verriest Medal from International Colour Vision Society

Wearable collision warning device may help patients with peripheral vision loss

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

IUPUI's Jason Meyer awarded $1.8 million NIH grant to explore how glaucoma develops in stem cells

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News